Related Experiment Video

Updated: Jan 19, 2026

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

17.1K

Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays

Hubert Scharnagl1, Tatjana Stojakovic1, Benjamin Dieplinger2

  • 1Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria.

Atherosclerosis
|September 9, 2019
PubMed

Insights

Commercial assays for Lipoprotein (a) [Lp(a)] show significant, concentration-dependent biases. Harmonization efforts are crucial for accurate cardiovascular disease risk assessment.

Area of Science:

  • Clinical Chemistry
  • Cardiovascular Diagnostics
  • Biomarker Quantification

Background:

  • Lipoprotein (a) [Lp(a)] is a causal risk factor for cardiovascular disease (CVD).
  • Accurate Lp(a) measurement is essential for clinical risk assessment.
  • Existing quantification methods require evaluation.

Purpose of the Study:

  • To compare the performance of commercially available immunochemical assays for Lp(a).
  • To identify discrepancies in Lp(a) measurements across different assays and concentrations.

Main Methods:

  • Six different commercial Lp(a) assays (mg/dl and nmol/l) were evaluated using 144 serum samples.
  • Assays were calibrated using manufacturer-provided materials.
  • Apolipoprotein (a) phenotyping was performed using SDS-agarose gel electrophoresis and immunoblotting.

Main Results:

  • High correlation (r > 0.90) was observed between most assays.
  • Assays showed significant divergence from reference values, with biases ranging from -8% to +22%.
  • Discrepancies were concentration-dependent and non-linear, with some assays overestimating Lp(a) at higher levels.

Conclusions:

  • Commercial Lp(a) assays exhibit variable calibration and significant, non-linear biases.
  • Observed biases are not fully explained by apolipoprotein (a) phenotypes.
  • International harmonization of Lp(a) assays is necessary for reliable clinical use.
Abstract

Keywords:
AtherosclerosisHarmonizationLipoprotein (a) assaysMyocardial infarction

More Related Videos

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification10:39

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

Published on: November 28, 2016

11.7K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.4K

Related Concept Videos

Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance01:25

Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance

In healthy individuals, serum creatinine levels remain stable due to a balance between its constant production—primarily from muscle metabolism—and renal excretion. Creatinine is freely filtered by the glomeruli, making it a valuable marker for estimating renal function. When the glomerular filtration rate (GFR) decreases, the kidneys can only eliminate less creatinine, causing serum levels to rise.Serum creatinine concentration is widely used to estimate creatinine clearance...
189
A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Measuring biomarkers in complex biological samples is increasingly guiding clinical decision-making. We describe a highly sensitive method to simultaneously measure cardiac myosin binding protein-C, creatine kinase MB, and cardiac troponin I in serum samples from subjects with myocardial infarction and healthy control...
17.1K
Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification10:39

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

This protocol describes the isolation and quantification of high-density lipoprotein small...
11.7K
Drug Concentrations: Measurements01:23

Drug Concentrations: Measurements

Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma...
1.1K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Several methods have been used for analyzing plasma lipoproteins; however, ultracentrifugation is still one of the most popular and reliable methods. Here, we describe a method regarding how to isolate lipoproteins from plasma using sequential density ultracentrifugation and how to analyze the apolipoproteins for both diagnostic and research...
12.4K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

We describe here a fluorometric cell-free biochemical assay for determination of HDL-lipid peroxidation. This rapid and reproducible assay can be used to determine HDL function in large scale studies and can contribute to our understanding of HDL function in human...
9.7K